Top

International Journal of Diabetes in Developing Countries

Published in:

01-12-2016 | Review Article

Pharmacogenetics and personalized treatment of type 2 diabetes mellitus

Authors: Pablo Yang, Verónica Ojeda Heredia, Dante M. Beltramo, Néstor W. Soria

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2016

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases in the world. An important difference in effectiveness and toxicity of hypoglycemic agents has been associated with the presence of genetic variants in people with T2DM. We conducted a literature review up November 2015 by combining keywords type 2 diabetes mellitus, hypoglycemic agents and pharmacogenetics (PKG). Metformin, sulfonylureas, and meglitinide drugs are widely used for the T2DM treatment, although new drugs in combination with metformin are administered. Genetic variants in proteins that function as carriers, channels, or metabolizing enzymes affect both the pharmacokinetics and pharmacodynamics of these agents. Significant progress in T2DM’s pharmacogenetics has been made; however, more studies involving a larger number of patients from different ethnic groups must be done. Furthermore, patients with T2DM generally are complex patients receiving hypolipidemic and hypotensive medications. Drug-drug interaction studies between these drugs must be done to really know the contribution of each polymorphism in drug effectiveness and/or toxicity.

Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104:1–9. doi:10.1055/s-0029-1211414.CrossRefPubMed

Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:2334–9. doi:10.1210/jc.2005-2323.CrossRefPubMed

Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23:245–9. doi:10.1016/j.ejim.2011.10.018.CrossRefPubMed

Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41:387–90. doi:10.1055/s-0029-1192019.CrossRefPubMed

Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract. 2007;77:58–61. doi:10.1016/j.diabres.2006.10.021.CrossRefPubMed

Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab. 2009;10:643–58.CrossRefPubMed

Wang J, Hu F, Feng T, Zhao J, Yin L, Li L, et al. Meta-analysis of associations between TCF7L2 polymorphisms and risk of type 2 diabetes mellitus in the Chinese population. BMC Med Genet. 2013;14:8. doi:10.1186/1471-2350-14-8.CrossRefPubMedPubMedCentral

Javorský M, Schroner Z. Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. Int J Endocrinol. 2013;2013:1–5. doi:10.1155/2013/374858.CrossRef

Schroner Z, Dobrikova M, Klimcakova L, Javorsky M, Zidzik J, Kozarova M, et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 2011;17:CR392–6.CrossRefPubMedPubMedCentral

10.

Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care. 2004;27:1394–8.CrossRefPubMed

11.

Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002;71:286–96. doi:10.1067/mcp.2002.122476.CrossRefPubMed

12.

Becker M, Visser L, Trienekens P, Hofman A, van Schaik R, Bhc S. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008;83:288–92. doi:10.1038/sj.clpt.6100273.CrossRefPubMed

13.

Shon J, Yoon Y, Kim M-J, Kim K, Lim Y, Liu K, et al. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005;59:552–63. doi:10.1111/j.1365-2125.2005.02364.x.CrossRefPubMedPubMedCentral

14.

Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72:326–32. doi:10.1067/mcp.2002.127495.CrossRefPubMed

15.

Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006;72:148–54. doi:10.1016/j.diabres.2005.09.019.CrossRefPubMed

16.

Tan B, Zhang Y, Chen X, Zhao X-H, Li G-X, Zhong D-F. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol. 2010;66:145–51. doi:10.1007/s00228-009-0736-2.CrossRefPubMed

17.

Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Clin Pharmacol Ther. 2002;72:562–71. doi:10.1067/mcp.2002.127913.CrossRefPubMed

18.

Malaisse WJ. Mechanism of action of a new class of insulin secretagogues. Exp Clin Endocrinol Diabetes. 1999;107(Suppl :S140–3). doi:10.1055/s-0029-1212170.

19.

Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358:1709–16. doi:10.1016/S0140-6736(01)06715-0.CrossRefPubMed

20.

Kirchheiner J, Meineke I, Müller G, Bauer S, Rohde W, Meisel C, et al. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet. 2004;43:267–78. doi:10.2165/00003088-200443040-00005.CrossRefPubMed

21.

Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou H-H. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur J Clin Pharmacol. 2013;69:407–13. doi:10.1007/s00228-012-1364-9.CrossRefPubMed

22.

Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77:468–78. doi:10.1016/j.clpt.2005.01.018.CrossRefPubMed

23.

Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol. 2008;48:311–21. doi:10.1177/0091270007311569.CrossRefPubMed

24.

Ruzilawati AB, Gan SH. CYP3A4 genetic polymorphism influences repaglinide’s pharmacokinetics. Pharmacology. 2010;85:357–64. doi:10.1159/000302731.CrossRefPubMed

25.

Huang Q, Yin J-Y, Dai X-P, Wu J, Chen X, Deng C-S, et al. Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol. 2010;66:1207–15. doi:10.1007/s00228-010-0882-6.CrossRefPubMed

26.

Xiang Q, Cui YM, Zhao X, Yan L, Zhou Y. The influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology. 2012;89:105–10. doi:10.1159/000336345.CrossRefPubMed

27.

Yu M, Xu X-J, Yin J-Y, Wu J, Chen X, Gong Z-C, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther. 2010;87:330–5. doi:10.1038/clpt.2009.242.CrossRefPubMed

28.

Yu W, Hu C, Zhang R, Wang C, Qin W, Lu J, et al. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin Pharmacol Ther. 2011;89:437–42. doi:10.1038/clpt.2010.351.CrossRefPubMed

29.

Huang Q, Yin J, Dai X, Pei Q, Dong M, Zhou Z, et al. IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. Acta Pharmacol Sin. 2010;31:709–17. doi:10.1038/aps.2010.47.CrossRefPubMedPubMedCentral

30.

Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25–33.CrossRefPubMed

31.

Strack T. Metformin: a review. Drugs Today (Barc). 2008;44:303–14.CrossRef

32.

Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–7. doi:10.2337/dc10-2361.CrossRefPubMedPubMedCentral

33.

Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22:820–7. doi:10.1097/FPC.0b013e3283559b22.CrossRefPubMedPubMedCentral

34.

Wang L, Weinshilboum R. Metformin pharmacogenomics: biomarkers to mechanisms. Diabetes. 2014;63:2609–10. doi:10.2337/db14-0609.CrossRefPubMedPubMedCentral

35.

Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012;22:659–66. doi:10.1097/FPC.0b013e3283561666.CrossRefPubMed

36.

Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83:273–80. doi:10.1038/sj.clpt.6100275.CrossRefPubMed

37.

Christensen MMH, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21:837–50. doi:10.1097/FPC.0b013e32834c0010.CrossRefPubMed

38.

Yang P, Nicolás JC, Galván CA, Vélez P, Da Ronco L, Díaz GT, et al. Effectiveness of metformin in patients with type II diabetes related to variants in the SLC22A1 gene | Eficácia de Metformina em doentes com diabetes tipo II, relacionado com variantes do gene SLC22A1. Acta Bioquim Clin Latinoam. 2014;48:229–35.

39.

Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84:559–62. doi:10.1038/clpt.2008.61.CrossRefPubMed

40.

Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes. 2009;58:745–9. doi:10.2337/db08-1028.CrossRefPubMedPubMedCentral

41.

Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93:186–94. doi:10.1038/clpt.2012.210.CrossRefPubMed

42.

Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, et al. A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clin Pharmacol Ther. 2011;90:674–84. doi:10.1038/clpt.2011.165.CrossRefPubMedPubMedCentral

43.

Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, Coleman RL, Tavendale R, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43:117–20. doi:10.1038/ng.735.CrossRefPubMed

44.

Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2012;18(Suppl 2):S10–5.

45.

Kung J, Henry RR. Thiazolidinedione safety. Expert Opin Drug Saf. 2012;11:565–79. doi:10.1517/14740338.2012.691963.CrossRefPubMed

46.

Wang L, Teng Z, Cai S, Wang D, Zhao X, Yu K. The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol. 2013;8:118. doi:10.1186/1746-1596-8-118.PubMedPubMedCentral

47.

Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev. 2004;25:899–918. doi:10.1210/er.2003-0036.CrossRefPubMed

48.

Ramírez-Salazar M, Pérez-Luque E, Fajardo-Araujo M, Garza SM, Malacara JM. Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women. Menopause. 2008;15:1151–6. doi:10.1097/gme.0b013e31816d5b2d.CrossRefPubMed

49.

Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, et al. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 2005;78:202–8. doi:10.1016/j.clpt.2005.04.013.CrossRefPubMed

50.

Hsieh M-C, Lin K-D, Tien K-J, Tu S-T, Hsiao J-Y, Chang S-J, et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism. 2010;59:1139–44. doi:10.1016/j.metabol.2009.10.030.CrossRefPubMed

51.

Pei Q, Huang Q, Yang G, Zhao Y, Yin J, Song M, et al. PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients’ response to pioglitazone in China. Acta Pharmacol Sin. 2013;34:255–61. doi:10.1038/aps.2012.144.CrossRefPubMed

52.

Makino H, Shimizu I, Murao S, Kondo S, Tabara Y, Fujiyama M, et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at −420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Endocr J. 2009;56:1049–58.CrossRefPubMed

53.

Wang J, Bao Y, Hu C, Zhang R, Wang C, Lu J, et al. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta Pharmacol Sin. 2008;29:252–8. doi:10.1111/j.1745-7254.2008.00744.x.CrossRefPubMed

54.

Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10:1489–510. doi:10.2217/pgs.09.82.CrossRefPubMedPubMedCentral

55.

Stage TB, Christensen MMH, Feddersen S, Beck-Nielsen H, Brøsen K. The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARγ on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics. 2013;23:219–27. doi:10.1097/FPC.0b013e32835f91fc.CrossRefPubMed

56.

Zhou F, Huang Q, Dai X, Yin J, Wu J, Zhou H, et al. Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban2011;36:949–57. doi:10.3969/j.issn.1672-7347.2011.10.004.

57.

Kang ES, Park SY, Kim HJ, Ahn CW, Nam M, Cha BS, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care. 2005;28:1139–44. doi:10.2337/diacare.28.5.1139.CrossRefPubMed

58.

van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4:1189–95.CrossRefPubMedPubMedCentral

59.

Andrulionyte L, Kuulasmaa T, Chiasson J-L, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes. 2007;56:1181–6. doi:10.2337/db06-1110.CrossRefPubMed

60.

Andrulionytè L, Zacharova J, Chiasson J-L, Laakso M. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 2004;47:2176–84. doi:10.1007/s00125-004-1577-2.CrossRefPubMed

61.

Scheen AJ. A review of gliptins for 2014. Expert Opin Pharmacother. 2015;16:43–62. doi:10.1517/14656566.2015.978289.CrossRefPubMed

62.

Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol. 2014;10:787–812. doi:10.1517/17425255.2014.907274.CrossRefPubMed

63.

Zimdahl H, Ittrich C, Graefe-Mody U, Boehm BO, Mark M, Woerle H-J, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 2014;57:1869–75. doi:10.1007/s00125-014-3276-y.CrossRefPubMedPubMedCentral

64.

Asakura M, Fujii H, Atsuda K, Itoh T, Fujiwara R. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Drug Metab Dispos. 2015;43:477–84. doi:10.1124/dmd.114.062331.CrossRefPubMed

65.

Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept. 2005;130:1–6. doi:10.1016/j.regpep.2005.05.001.CrossRefPubMed

66.

Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep. 2010;10:124–32. doi:10.1007/s11892-010-0102-x.CrossRefPubMed

67.

de Luis DA, Ovalle HF, Soto GD, Izaola O, de la Fuente B, Romero E. Role of genetic variation in the cannabinoid receptor gene (CNR1) (G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med. 2014;62:324–7. doi:10.231/JIM.0000000000000032.CrossRefPubMed

68.

Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62:1279–84. doi:10.1111/j.1742-1241.2008.01829.x.CrossRefPubMed

69.

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373–81. doi:10.1016/j.diabres.2013.12.052.CrossRefPubMed

70.

Yu L, Lv J-C, Zhou X, Zhu L, Hou P, Zhang H. Abnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patients. Hum Genet. 2011;129:335–44. doi:10.1007/s00439-010-0927-z.CrossRefPubMed

71.

Enigk U, Breitfeld J, Schleinitz D, Dietrich K, Halbritter J, Fischer-Rosinsky A, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12:1119–26. doi:10.2217/pgs.11.69.CrossRefPubMed

72.

Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes Metab. 2013;15:280–3. doi:10.1111/dom.12024.CrossRefPubMed

73.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract. 2016;22:84–113. doi:10.4158/EP151126.CS.CrossRefPubMed

Title: Pharmacogenetics and personalized treatment of type 2 diabetes mellitus
Authors: Pablo Yang
Verónica Ojeda Heredia
Dante M. Beltramo
Néstor W. Soria
Publication date: 01-12-2016
Publisher: Springer India
Published in: International Journal of Diabetes in Developing Countries / Issue 4/2016
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-016-0517-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Diabetes and data in many forms

An unusual cause for facial nerve palsy: mucormycosis

Glycemic control is difficult to attain in type 2 diabetes mellitus despite insulin therapy

Impact of selected pre-processing techniques on prediction of risk of early readmission for diabetic patients in India

Phylogenetic and promoter analysis of islet amyloid polypeptide gene causing type 2 diabetes in mammalian species

Predictive risk modelling for early hospital readmission of patients with diabetes in India

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage